Pentapharm

Executive Summary

Pentapharm AG, headquartered in Basel, Switzerland, is a privately held biotech company with a rich heritage dating back to 1947. The company specializes in the research, development, and manufacturing of active pharmaceutical ingredients (APIs) and diagnostic reagents derived from natural sources, particularly snake venom. Its core focus lies in blood coagulation disorders and thrombosis, offering a product portfolio that includes biochemicals, peptide substrates, inhibitors, and IVD reagent kits. By leveraging unique venom-derived biomolecules, Pentapharm has carved a niche in hemostasis management, supplying both therapeutic APIs and diagnostic tools to the global healthcare market. As a long-standing player in the biologics and hematology space, Pentapharm benefits from decades of expertise in natural product extraction and characterization. However, as a private company without disclosed financials or recent pipelines, its growth trajectory is less transparent. The company's competitive advantage stems from its proprietary access to rare snake venoms and established manufacturing processes. Near-term opportunities may include expanding its diagnostic kit portfolio or forming strategic partnerships for new anticoagulant therapies. While lacking imminent catalysts, Pentapharm's historical stability and specialization position it for steady, niche growth in the hemostasis market.

Upcoming Catalysts (preview)

• Q3 2026Launch of a novel rapid diagnostic test for coagulation disorders60% success
• TBDStrategic partnership with a major pharmaceutical company for venom-derived API supply70% success
• Q1 2027Expansion into emerging markets with new IVD reagent kit approvals50% success